 |
| Adjuvants |
|
| Improved immune response |
| The efficacy of the Ingelvac M hyo has been demonstrated using a range of different types of study. |
|
| Firstly, laboratory studies have compared the efficacy of Ingelvac M hyo with competitor mycoplasma vaccines - one and two-shot products - on stimulation of the pig's immune system. This efficacy has been measured on both the level of antibodies produced (humoral immunity ) and the more significant and more specific cell-mediated immune response. |
|
Piglets were vaccinated at three weeks of age with Ingelvac M hyo or a competitor one-shot product and at 3 and 5 weeks of age with a competitor two-shot product. Two other non-vaccinated groups were included in the study. |
|
All animals except for one of the non-vaccinated groups were experimentally infected with M hyo 2 weeks later. Animals were slaughtered 4 weeks later. |
|
|
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
Day 0 |
|
|
|
Day 14 |
|
|
|
Day 29 |
|
|
|
Day 57 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Ingelvac M hyo | |
|
|
X |
|
|
|
|
|
|
|
Infection |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Competitor A, |
|
|
|
X | |
|
|
|
|
|
|
Infection | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Competitor B, |
|
|
|
X | |
|
|
X | |
|
|
Infection | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Positive control |
|
|
|
|
|
|
|
|
|
|
|
Infection | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
||||||||||||||||||||
|
| Humoral immunity |
The following table illustrates that already 29 days post vaccination with Ingelvac M hyo (before challenge), 80% of the piglets had developed antibodies. In contrast, only 55% of the pigs vaccinated with the two-shot vaccine and 0% of the competitor one shot, had done so. |
|
| Percentage of antibody-positive piglets (tested by ELISA) on day 29 post vaccination: |
|
 |
One-shot vaccine = 80% |
|
|
||
|
Competitor A, two-shot vaccine = 55% | |
|
||
|
Competitor One-shot vaccine = 0% | |
|
||
|
Negative controls | |
|
||
|
Positive controls = 0% | |
|
||
|
| Cell-mediated immune response |
Cell-mediated immunity was measured by determining the interferon gamma stimulation index. Interferon is produced within a few hours of infection. Animals whose immune system has already been challenged by a specific pathogen excrete a large quantity of interferon gamma upon renewed contact with the pathogen. The higher the interferon gamma excretion in response to infection, the better the specific, cellular defence. |
|
Percentage of animals with cell-mediated immune responses (ELISPOT) after infection has occurred |
|
 |
|
The results are shown in the following graph. The group that was vaccinated with Ingelvac M hyo was the only group where significantly more animals had a positive interferon gamma stimulation index already 29 and 44 days post vaccination. |
|
 |
|
| © 2006 Boehringer Ingelheim Ltd UK. All rights reserved. Company Registration Number: 711858 Access to and use of this website is subject to our Terms of use which users are deemed to accept by accessing this website. Any queries concerning the design of the site please send an email to the webmaster. |
|
 |
|
||
|
Effects of depot shots |
|
|
|
|
 |
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||